115 filings
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4:30pm
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4:20pm
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4:15pm
6-K
CVAC
CureVac N.V.
16 Apr 24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4:15pm
6-K
CVAC
CureVac N.V.
4 Apr 24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4:15pm
6-K
znf8lzg9kept1jf
17 Jan 24
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
9:02am
6-K
tp7n6 gtq4
5 Jan 24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
4:15pm
6-K
0lddsvf6gc1pu77sf
19 Dec 23
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
4:30pm
6-K
cxrp7cmni9sb
14 Nov 23
Current report (foreign)
4:15pm
6-K
ivvaugql vcbd83zau1h
14 Nov 23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
4:15pm
6-K
v7dp kvhct8d
1 Nov 23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
4:45pm
6-K
hifjn5t3 z94vklg2ix
28 Sep 23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
4:30pm
6-K
g2ss1xdxr3tmszvc2m2t
12 Sep 23
Current report (foreign)
4:30pm
6-K
5chds5n68 wdri
17 Aug 23
Current report (foreign)
4:30pm
6-K
qwcwy2l
17 Aug 23
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
4:30pm
6-K
fhagdvxdo71r4
1 Aug 23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
4:15pm
6-K
fcz6440z4bfgb v6bvk
14 Jul 23
CureVac Announces Update to the Management Team
4:01pm
6-K
5lbb0yjjll
13 Jul 23
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
4:01pm
6-K
cwnb 1qmf79i24a
22 Jun 23
Current report (foreign)
4:01pm
6-K
tewc1g7bgoe 8mgzlu7
20 Jun 23
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
4:45pm